Observers Give Mixed Reviews To Media's 'Dollymania'

In the seven weeks since the announcement of the successful cloning of a lamb called Dolly from an adult ewe, the scientific community has had time to reflect on what they've read, heard, or watched in the mass media. Among the scientists and bioethicists interviewed by The Scientist, there is unanimous excitement about the research itself. Despite this enthusiasm, observers and participants have a mixed reaction to the initial media coverage of the Dolly story. Some are pleased with news repor

Written byKaren Young Kreeger
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

In the seven weeks since the announcement of the successful cloning of a lamb called Dolly from an adult ewe, the scientific community has had time to reflect on what they've read, heard, or watched in the mass media. Among the scientists and bioethicists interviewed by The Scientist, there is unanimous excitement about the research itself. Despite this enthusiasm, observers and participants have a mixed reaction to the initial media coverage of the Dolly story. Some are pleased with news reports, while others say journalists missed certain important scientific points and resorted to sensationalism.

Photo: AP/World Wide Photos A BREED APART: Dolly, the infamous cloned Finn Dorset lamb, sparked a maelstrom of drama and media hype. "Excessive" is the one word that Keith Campbell, a senior research scientist at the Roslin Institute near Edinburgh, Scotland, where the cloning experiments took place, uses to describe media events surrounding the announcement. Campbell ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies